Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo

Clinical Cancer Research

Volumn 13, Issue 5, 2007, Pages 1611-1619

  Adhami, Vaqar Mustafa ^a   Malik, Arshi ^a   Zaman, Najia ^a   Sarfaraz, Sami ^a   Siddiqui, Imtiaz Ahmad ^a   Syed, Deeba Nadeem ^a   Afaq, Farrukh ^a   Pasha, Farrukh Sierre ^a   Saleem, Mohammad ^a   Mukhtar, Hasan ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 6; CASPASE 9; CELECOXIB; EPIGALLOCATECHIN GALLATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BAX; PROTEIN PRECURSOR; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; BEVERAGES; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2 INHIBITORS; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLAVONOIDS; HUMANS; MALE; MICE; MICE, NUDE; NITROBENZENES; PHENOLS; PROSTATIC NEOPLASMS; PYRAZOLES; SULFONAMIDES; TEA;

EID: 33947404063     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2269     Document Type: Article

References (49)

1. Kelloff GJ, Sigman CC, Greenwald P. Cancer chemoprevention: progress and promise. Eur J Cancer 1999; 35:2031-8.
2. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003;3:768-80.
3. Gupta S, Ahmad N, Mukhtar H. Prostate cancer chemoprevention by green tea. Semin Urol Oncol 1999; 17:70-6.
4. Mukhtar H, Ahmad N. Cancer chemoprevention: future holds in multiple agents. Toxicol Appl Pharmacol 1999;158:207-10.
5. McCarty MF. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integr Cancer Ther 2004;3: 349-80.
6. Narayanan BA, Narayanan NK, Pittman B, Reddy BS. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 2004;10:7727-37.
7. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev 2006;6: 130-40.
8. Narayanan BA, Narayanan NK, Pttman B, Reddy BS. Adenocarcinoma of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition. Prostate 2006; 66:257-65.
9. Velmurugan B, Mani A, Nagini S. Combination of S-allylcysteine and lycopene induces apoptosis by modulating Bcl-2, Bax, Bim and caspases during experimental gastric carcinogenesis. Eur J Cancer Prev 2005;14:387-93.
10. Lin J, Hsiao PW, Chiu TH, Chao JI. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. Biochem Pharmacol 2005;70:658-67.
11. Tortora G, Caputo R, Damiano V, et al. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity. Clin Cancer Res 2003;9:866-71.
12. Banerjee S, Zhang Y, Ali S, et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 2005;65:9064-72.
13. Khor TO, Keum YS, Lin W, et al. Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Res 2006;66:613-21.
14. Anderson WF, Umar A, Hawk ET. Cyclooxygenase inhibition in cancer prevention and treatment. Expert Opin Pharmacother 2003;4:2193-204.
15. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000;42: 73-8.
16. Gupta S, Adhami VM, Subbarayan M, et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2004;64: 3334-43.
17. Dandekar DS, Lopez M, Carey RI, Lokeshwar BL. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer 2005;115:484-92.
18. Dandekar DS, Lokeshwar BL. Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs. Clin Cancer Res 2004;10:8037-47.
19. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci U S A 2001;98:10350-5.
20. Sartor L, Pezzato E, Dona M. Prostate carcinoma and green tea: (-)epigallocatechin-3-gallate inhibits inflammation-triggered MMP-2 activation and invasion in murine TRAMP model. Int J Cancer 2004;112: 823-9.
21. Caporali A, Davalli P, Astancolle S. The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis 2004;25: 2217-24.
22. Adhami VM, Ahmad N, Mukhtar H. Molecular targets for green tea in prostate cancer prevention. J Nutr 2003;133:2417-24S.
23. Hussain T, Gupta S, Adhami VM, Mukhtar H. Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. Int J Cancer 2005; 113:660-9.
24. Sabichi AL, Lippman SM. COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer. Semin Oncol 2004;31:36-44.
25. Pruthi RS, Derksen JE, Moore D. A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU Int 2004;93:275-8.
26. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006;66:1234-40.
27. Jian L, Xie LP, Lee AH, Bin CW. Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer 2004;108: 130-5.
28. Spektor G, Fuster V. Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk-where are we now? Nat Clin Pract Cardiovasc Med 2005;2:290-300.
29. Brophy JM. Celecoxib and cardiovascular risks. Expert Opin Drug Saf 2005;4:1005-15.
30. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989;24:148-54.
31. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
32. Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996;52: 237-45.
33. Patel Ml, Subbaramaiah K, Du B, et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005;11:1999-2007.
34. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992;75:1046-53.
35. Stattin P, Rinaldi S, Biessy C, Stenman UH, Hallmans G, Kaaks R. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol 2004;22:3104-12.
36. Gennigens C, Menetrier-Caux C, Droz JP. Insulin-like growth factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol 2006;58:124-45.
37. Liao Y, Abel U, Grobholz R, et al. Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade. Hum Pathol 2005;36:1186-96.
38. Adhami VM, Siddiqui IA, Ahmad N, Gupta S, Mukhtar H. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 2004;64:8715-22.
39. Li L, Yu H, Schumacher F, Casey G, Witte JS. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control 2003;14: 721-6.
40. Zhang X, Chen ZG, Choe MS, et al. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 2005;11:6261-9.
41. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005; 23:254-66.
42. Rainsford KD. Introduction - the coxib controversies. Inflammopharmacology 2005;13:331-41.
43. Melnikova I. Future of COX2 inhibitors. Nat Rev Drug Discov 2005;4:453-4.
44. Albini A, Noonan DM. Rescuing COX-2 inhibitors from the waste bin. J Natl Cancer Inst 2005;97: 859-60.
45. Reddy BS, Patlolla JM, Simi B, Wang SH, Rao CV. Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in ω-3 polyunsaturated fatty acids. Cancer Res 2005; 65:8022-7.
46. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN. Bcl-2/Bax: a rheostat that regulates an antioxidant pathway and cell death. Semin Cancer Biol 1993;4:327-32.
47. Bozec A, Ruffion A, Decaussin M, et al. Activation of caspases-3, -6, and -9 during finasteride treatment of benign prostatic hyperplasia. J Clin Endocrinol Metab 2005;90:17-25.
48. Golstein P, Aubry L, Levraud JP. Cell-death alternative model organisms: why and which? Nat Rev Mol Cell Biol 2003;4:798-807.
49. Kashfi K, Rigas B. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol 2005;70:969-86.